Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.00 segons. 
1.
15 p, 418.2 KB Reducing residual thrombotic risk in patients with peripheral artery disease : impact of the COMPASS trial / Hernández, José Luis (Instituto de Investigación Sanitaria Valdecilla (Santander, País Basc)) ; Lozano, Francisco S (Hospital Clínico Universitario (Salamanca)) ; Riambau, Vincent (Hospital Clínic i Provincial de Barcelona) ; Almendro-Delia, Manuel (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Cosín-Sales, Juan (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Bellmunt-Montoya, Sergi (Hospital Universitari Vall d'Hebron) ; Garcia-Alegria, Javier (Hospital Costa del Sol (Marbella)) ; Garcia-Moll, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Gomez-Doblas, Juan José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Gonzalez-Juanatey, José R (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares) ; Suarez Fernández, Carmen (Instituto de Investigación Hospital Universitario de la Princesa) ; Universitat Autònoma de Barcelona
Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE). [...]
2020 - 10.7573/dic.2020-5-5
Drugs in Context, Vol. 9 (july 2020)  
2.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.